BUTAZOLIDIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUTAZOLIDIN is an oral small-molecule capsule approved by Novartis in 1997 with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team likely focused on maximizing remaining patent-protected revenue and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job openings are currently linked to BUTAZOLIDIN, reflecting its late-lifecycle stage and approaching loss of exclusivity. Career opportunities on this product are limited; roles available would focus on managing decline and transition planning rather than growth.
Brand ManagerField Sales Representative
Worked on BUTAZOLIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.